DRUG

bimekizumab

Plaque psoriasis (FDA 2023)

26 hypotheses across 6 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

bimekizumab appears in hypotheses across 6 disease domains: ALS, Depression, Epilepsy, Inflammatory bowel disease, Multiple sclerosis, Pancreatic cancer. Shared mediators that recur across at least two of those domains: IL-17A, IL-17F.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for bimekizumab

ALS 3

Mediator Outcome Score Tier Lit. status Trial
IL-17A neurite length 0.248 Mid novel signal none
IL-17F motor neuron survival 0.248 Mid novel signal none
IL-17A motor neuron viability 0.248 Mid novel signal none

Depression 1

Mediator Outcome Score Tier Lit. status Trial
IL-17A antidepressant treatment resistance 0.248 Mid novel signal none

Epilepsy 4

Mediator Outcome Score Tier Lit. status Trial
IL-17A neural progenitor proliferation 0.248 Mid novel signal none
IL-17A LTP dysfunction 0.248 Mid novel signal none
IL-17A hippocampal neuronal death 0.248 Mid novel signal none
IL-17A anxiety 0.248 Mid novel signal none

Inflammatory bowel disease 8

Mediator Outcome Score Tier Lit. status Trial
IL-17A inflammatory bowel disease 0.318 High reproduces known preclinical only
IL-17A IBD 0.289 High partial evidence preclinical only
IL-17A ulcerative colitis 0.289 High partial evidence none
IL-17A Crohn's disease 0.248 Mid partial evidence none
IL-17F inflammatory bowel disease 0.248 Mid reproduces known preclinical only
IL-17A endoscopic severity 0.248 Mid novel signal none
IL-17A Behcet's uveitis 0.248 Mid novel signal none
IL-17A fibrosis 0.248 Mid partial evidence none

Multiple sclerosis 8

Mediator Outcome Score Tier Lit. status Trial
IL-17A cognitive impairment 0.289 High novel signal none
IL-17A BBB dysfunction 0.248 Mid novel signal none
IL-17A EAE severity 0.248 Mid novel signal none
IL-17A EAE 0.248 Mid novel signal none
IL-17A response to interferon-beta therapy 0.248 Mid novel signal none
IL-17A EAE susceptibility 0.248 Mid novel signal none
IL-17A CNS autoimmunity 0.248 Mid novel signal preclinical only
IL-17A intestinal homeostasis 0.248 Mid novel signal none

Pancreatic cancer 2

Mediator Outcome Score Tier Lit. status Trial
IL-17A islet β-cell apoptosis 0.248 Mid novel signal none
IL-17A acinar-ductal metaplasia 0.248 Mid novel signal none

Clinical trials

59 registered trials for bimekizumab

Source: ClinicalTrials.gov

← All drugs